Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Colorectal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2Esophageal Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Recurrence 1Papillomavirus Infections 1Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Insulin-Like Growth Factor I, Resistance To 1Gliosarcoma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Brain Neoplasms 1

Interventions

Temozolomide 93Radiotherapy 66Bevacizumab 35Radiation 22Carmustine 21Erlotinib Hydrochloride 17Chemotherapy, Adjuvant 17Irinotecan 16Magnetic Resonance Spectroscopy 13Radiotherapy, Conformal 11O(6)-benzylguanine 11Surgical Procedures, Operative 10Radiotherapy, Intensity-Modulated 10sargramostim 9Sirolimus 9Imatinib Mesylate 9Carboplatin 9temsirolimus 8motexafin gadolinium 7Thalidomide 7Gene Expression Profiling 7aldesleukin 6Sorafenib 6Radiosurgery 6Immunohistochemistry 6Hydroxyurea 6Gefitinib 6Filgrastim 6Everolimus 6Etoposide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Gliosarcoma × Receptor Protein-Tyrosine Kinases × Clear all
NCT01753713 2017-12-12

Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma

Case Comprehensive Cancer Center

Phase 2 Completed
33 enrolled 14 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡